-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On July 4, the CRO concept sector of Hong Kong stocks changed, and many stocks rose significant.
As of the close, Zhaoyan New Drug rose by the daily limit, with an increase of 10%, WuXi Biologics rose by more than 8%, GenScript Biotechnology, Kay Laying rose more than 7%, Tiger Pharmaceuticals, WuXi PharmaTech and others followed su.
As of the close, Zhaoyan New Drug's price was 1261 yuan, the turnover was 866 million, the turnover rate was 18%, and the price-earnings (TTM) was 89According to the data, the company's main business includes drug non-clinical research services (ie non-clinical CRO business), drug clinical trials and related services (ie clinical business), and the supply of experimental mode.
Among them, non-clinical CRO business is the company's core business, including drug non-clinical safety evaluation, pharmacodynamics research, pharmacokinetic research services and drug screeni.
WuXi Biologics closed at HK$755, with a turnover of 016 billion, a turnover rate of 63%, and a price-earnings (TTM) of 79WuXi Biologics is an investment holding company that mainly provides biologics discovery, development and production servic.
Its technology platforms include WuXiBody TM bispecific antibody technology platform and antibody-drug conjugate (ADC) technology platform, e.
Customers manufacture vaccines to supply global marke.
GenScript Biotechnology quoted HK$370, with a turnover of 306 million, a turnover rate of 48%, and a loss in price-earnings (TT.
According to the data, GenScript's business scope covers four major areas: life science services and products, industrial synthetic biological products, biopharmaceutical CDMO and cell thera.
Asymchem's quotation was 3050 yuan, the turnover was 500 billion, the turnover rate was 57%, and the price-earnings (TTM) was 59
The company is a domestic CDMO (pharmaceutical contract custom R&D and production) enterprise, which is mainly committed to the technological innovation and commercial application of global pharmaceutical processes, and provides one-stop CMC services for drug R&D and production for large and medium-sized pharmaceutical and biotechnology companies at home and abro.
On the news, the "Regulations on the Implementation of the Drug Administration Law (Draft for Comments)" recently released by the State Food and Drug Administration completed the collection of commen.
This is the first major revision of the Regulations since it came into force on September 15, 2002, increasing from 80 articles of more than 12,000 words in the current regulations to 181 articles of more than 29,000 wor.
This consultation draft is encouraging drug innovation from multiple perspectiv.
For example, in terms of institutional dividends, the relevant provisions in the consultation draft include: Article 9 "Encourage innovation", Article 10 "Accelerate the market channel", Article 20 " Change of sponsor”, Article 38 “Patent Link”, e.
In terms of industry promotion, the relevant provisions in the draft for comments include: Article 29 “Rare Diseases”, Article 39 “Promoting the Development of Generic Drugs”, Article 40 “ Data Protection"e.
In general, the new regulations will be more beneficial to innovative pharmaceutical companies, and will further promote the availability of medicines, allowing people to use more new and good medicin.
Southwest Securities previously stated that, driven by cost advantages, overseas CXO production capacity continued to shift to China, and the rise of domestic innovative drugs further brought incremental space for the CXO indust.
It is expected that the performance of the CXO sector is expected to maintain rapid growth with high certain.
Minsheng Securities pointed out that from the perspective of revenue growth in the first quarter of this year, CXO still maintains a very rapid growth trend, which includes not only the performance growth brought about by the abundant endogenous orders of CXO, but also the growth brought about by the gradual realization of Pfizer’s new crown drug orde.
Generally speaking, the CXO sector can still maintain high growth in the second quarter, which is outstanding in the pharmaceutical indust.
In addition, the capital expenditure of domestic CXO enterprises is obviously accelerating, and it is expected to maintain a high growth rate this year, and the construction in progress is also showing a rapid growth trend, especially WuXi AppTec's obvious expansion of production, which reflects the confidence in the rapid development of the indust.
In addition, gene and cell therapy have opened up new growth spa.
For example, Proton Bio has built a CDMO platform that integrates plasmids, viral vectors and cell therapy produc.
The current development momentum is good, and the orders in hand are growing rapidly, opening up new growth spa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
As of the close, Zhaoyan New Drug rose by the daily limit, with an increase of 10%, WuXi Biologics rose by more than 8%, GenScript Biotechnology, Kay Laying rose more than 7%, Tiger Pharmaceuticals, WuXi PharmaTech and others followed su.
As of the close, Zhaoyan New Drug's price was 1261 yuan, the turnover was 866 million, the turnover rate was 18%, and the price-earnings (TTM) was 89According to the data, the company's main business includes drug non-clinical research services (ie non-clinical CRO business), drug clinical trials and related services (ie clinical business), and the supply of experimental mode.
Among them, non-clinical CRO business is the company's core business, including drug non-clinical safety evaluation, pharmacodynamics research, pharmacokinetic research services and drug screeni.
WuXi Biologics closed at HK$755, with a turnover of 016 billion, a turnover rate of 63%, and a price-earnings (TTM) of 79WuXi Biologics is an investment holding company that mainly provides biologics discovery, development and production servic.
Its technology platforms include WuXiBody TM bispecific antibody technology platform and antibody-drug conjugate (ADC) technology platform, e.
Customers manufacture vaccines to supply global marke.
GenScript Biotechnology quoted HK$370, with a turnover of 306 million, a turnover rate of 48%, and a loss in price-earnings (TT.
According to the data, GenScript's business scope covers four major areas: life science services and products, industrial synthetic biological products, biopharmaceutical CDMO and cell thera.
Asymchem's quotation was 3050 yuan, the turnover was 500 billion, the turnover rate was 57%, and the price-earnings (TTM) was 59
The company is a domestic CDMO (pharmaceutical contract custom R&D and production) enterprise, which is mainly committed to the technological innovation and commercial application of global pharmaceutical processes, and provides one-stop CMC services for drug R&D and production for large and medium-sized pharmaceutical and biotechnology companies at home and abro.
On the news, the "Regulations on the Implementation of the Drug Administration Law (Draft for Comments)" recently released by the State Food and Drug Administration completed the collection of commen.
This is the first major revision of the Regulations since it came into force on September 15, 2002, increasing from 80 articles of more than 12,000 words in the current regulations to 181 articles of more than 29,000 wor.
This consultation draft is encouraging drug innovation from multiple perspectiv.
For example, in terms of institutional dividends, the relevant provisions in the consultation draft include: Article 9 "Encourage innovation", Article 10 "Accelerate the market channel", Article 20 " Change of sponsor”, Article 38 “Patent Link”, e.
In terms of industry promotion, the relevant provisions in the draft for comments include: Article 29 “Rare Diseases”, Article 39 “Promoting the Development of Generic Drugs”, Article 40 “ Data Protection"e.
In general, the new regulations will be more beneficial to innovative pharmaceutical companies, and will further promote the availability of medicines, allowing people to use more new and good medicin.
Southwest Securities previously stated that, driven by cost advantages, overseas CXO production capacity continued to shift to China, and the rise of domestic innovative drugs further brought incremental space for the CXO indust.
It is expected that the performance of the CXO sector is expected to maintain rapid growth with high certain.
Minsheng Securities pointed out that from the perspective of revenue growth in the first quarter of this year, CXO still maintains a very rapid growth trend, which includes not only the performance growth brought about by the abundant endogenous orders of CXO, but also the growth brought about by the gradual realization of Pfizer’s new crown drug orde.
Generally speaking, the CXO sector can still maintain high growth in the second quarter, which is outstanding in the pharmaceutical indust.
In addition, the capital expenditure of domestic CXO enterprises is obviously accelerating, and it is expected to maintain a high growth rate this year, and the construction in progress is also showing a rapid growth trend, especially WuXi AppTec's obvious expansion of production, which reflects the confidence in the rapid development of the indust.
In addition, gene and cell therapy have opened up new growth spa.
For example, Proton Bio has built a CDMO platform that integrates plasmids, viral vectors and cell therapy produc.
The current development momentum is good, and the orders in hand are growing rapidly, opening up new growth spa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.